Wordt geladen...
Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis
BACKGROUND: Sitagliptin, a highly selective dipeptidyl peptidase-4 inhibitor, is the first in a new class of oral antihyperglycemic agents (AHAs) for the treatment of patients with type 2 diabetes. Type 2 diabetes is a life-long disease requiring chronic treatment and management. Therefore, robust a...
Bewaard in:
| Hoofdauteurs: | , , , , , , , |
|---|---|
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
BioMed Central
2008
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2605739/ https://ncbi.nlm.nih.gov/pubmed/18954434 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1472-6823-8-14 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|